Riboflavin-ultraviolet A (UVA) collagen cross-linking (CXL) has been applied in clinical settings to prevent the progression of keratoconus and corneal dilatation caused by other reasons in past decades. As CXL with riboflavin-UVA can enhance the stiffness of collagen-rich tissues, this technique has been further used on sclera to investigate as a safe and effective myopia prevention treatment. Despite the riboflavin-UVA scleral CXL is still in the animal and in vitro experimental phases and the mechanism is not very clear, it is promising to control myopia development clinically. In this article, researches on the laboratory experiments of riboflavin-UVA scleral CXL on scheme exploration and mechanism were reviewed in order to provide more laboratory evidence for scleral CXL in clinical myopia prevention and control in the future.